Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of Tuesday, October 6, 2026.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
Obsidian Therapeutics Inc.
Market Cap
$14.17M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.92M
Return on Invested Capital (ROIC)
-157.90%
TTM Avg
-186.85%
3Y Avg
-152.06%
5Y Avg
-115.52%
Market Cap
$13.78M
Return on Invested Capital (ROIC)
-67.62%
TTM Avg
-48.11%
3Y Avg
-41.05%
5Y Avg
-37.60%
Market Cap
$13.66M
Return on Invested Capital (ROIC)
-57.53%
TTM Avg
-660.45%
3Y Avg
-553.22%
5Y Avg
-396.73%
Market Cap
$14.31M
Return on Invested Capital (ROIC)
-13.15%
TTM Avg
-23.00%
3Y Avg
-25.06%
5Y Avg
-54.51%
Market Cap
$13.71M
Return on Invested Capital (ROIC)
-91.74%
TTM Avg
-119.31%
3Y Avg
-112.64%
5Y Avg
-88.90%
Market Cap
$13.51M
Return on Invested Capital (ROIC)
-28.72%
TTM Avg
-40.11%
3Y Avg
-38.90%
5Y Avg
-32.17%
Market Cap
$14.98M
Return on Invested Capital (ROIC)
-48.04%
TTM Avg
-66.55%
3Y Avg
-57.55%
5Y Avg
-44.03%
Market Cap
$12.78M
Return on Invested Capital (ROIC)
-74.94%
TTM Avg
-273.26%
3Y Avg
-277.38%
5Y Avg
-186.51%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.17M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | -157.90% | -186.85% | -152.06% | -115.52% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | -67.62% | -48.11% | -41.05% | -37.60% |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | -57.53% | -660.45% | -553.22% | -396.73% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.31M | -13.15% | -23.00% | -25.06% | -54.51% |
| IN8bio, Inc. (INAB)vs › | $13.71M | -91.74% | -119.31% | -112.64% | -88.90% |
| Optimi Health Corp. (OPTH)vs › | $13.51M | -28.72% | -40.11% | -38.90% | -32.17% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | -48.04% | -66.55% | -57.55% | -44.03% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | -74.94% | -273.26% | -277.38% | -186.51% |
| Passage Bio, Inc. (PASG)vs › | $13.24M | -889.92% | -97.42% | -82.73% | -70.79% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
